SS18L2

Across TCGA pan-cancer cohorts, SS18L2 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of SS18L2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SS18L2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SS18L2 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, BLCA, and COAD are the cancer types where SS18L2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SS18L2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.869	<.001	9	view →
BLCA	All	All	+0.710	<.001	8	view →
COAD	Male	II,III,IV	+0.674	<.001	8	view →
STAD	Female	All	+1.245	<.001	7	view →
UCEC	All	III,IV	+1.287	<.001	6	view →
BRCA	All	All	+0.287	<.001	6	view →
KICH	Female	All	−0.964	<.001	5	view →
READ	All	All	+0.487	.003	5	view →
HNSC	Male	All	+0.392	.010	5	view →
CHOL	Male	All	+0.815	<.001	4	view →
THCA	All	All	−0.236	<.001	3	view →
ESCA	All	All	+0.880	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

SS18L2–LIHC

Open the LIHC breakdown →